Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | TEK | Q02763 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634063 | 0.87 | ALK (0.38) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13632997 | 0.86 | ALK (0.36) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633169 | 0.86 | ALK (0.37) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633113 | 0.85 | ALK (0.39) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13632935 | 0.84 | ALK (0.36) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633161 | 0.84 | JAK2 (0.37) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633110 | 0.84 | ALK (0.38) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13634061 | 0.84 | ALK (0.35) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633111 | 0.84 | ALK (0.36) | JAK2JAK1TYK2JAK3ALK | |
| SCHEMBL13633164 | 0.84 | ALK (0.47) | JAK2JAK1TYK2JAK3ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK2 1/4885JAK1 2/4885TYK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.